BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of stock options and restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The compensation committee approved options to purchase 36,700 shares and RSUs covering 89,750 shares of common stock.

The options were granted with an exercise price of $7.95 per share, matching BioCryst's closing price on August 1, 2025. Both options and RSUs will vest over four equal annual installments, starting one year from the grant date, with options having a 10-year term. These grants were made under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Potential dilution of existing shareholders from new equity grants

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock. The options and RSUs were granted as of August 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.95 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

How many shares were granted in BioCryst's (BCRX) latest inducement grants?

BioCryst granted options for 36,700 shares and RSUs covering 89,750 shares to 10 newly-hired employees.

What is the exercise price for BCRX's newly granted stock options?

The stock options were granted with an exercise price of $7.95 per share, equal to BioCryst's closing price on August 1, 2025.

What is the vesting schedule for BioCryst's (BCRX) new equity grants?

Both the options and RSUs vest in four equal annual installments, beginning on the one-year anniversary of the August 1, 2025 grant date.

How long is the term of BioCryst's newly granted stock options?

The stock options have a 10-year term from the grant date.

Under which rule were BioCryst's inducement grants made?

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for equity grants as employment inducements.